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Abstract
Background Body weight loss is a frequent complication after stroke, and its adverse effect on clinical outcome has been
shown in several clinical trials. The purpose of this prospective longitudinal single-centre observational study was to investigate
dynamical changes of body composition and body weight after ischemic stroke and an association with functional outcome.
Methods Sixty-seven consecutive patients (age 69 ± 11 years, body mass index 27.0 ± 4.1 kg/m2, 42% female patient,
mean ± SD) with acute ischemic stroke with mild to moderate neurological deﬁcit (National Institute of Health Stroke Scale
median 4, ranged 0–12) were analysed in the acute phase (4 ± 2 days) and at 12 months (389 ± 26 days) follow-up. Body com-
position was examined by dual energy X-ray absorptiometry. Cachexia was deﬁned according to the consensus deﬁnition by
body weight loss ≥5% within 1 year and additional clinical signs. Lean tissue wasting was considered if a ratio of upper and
lower limbs lean mass sum to squared height (kg/m2) was ≤5.45 kg/m2 for female patient and ≤7.25 kg/m2 for male patient.
Results According to the body weight changes after 12months, 42 (63%) patients had weight gain or stable weight, 11 (16%)
patients had moderate weight loss, and 14 (21%) patients became cachectic. A relative decline of 19% of fat tissue and 6.5% of
lean tissue was observed in cachectic patients, while no changes of lean tissue were observed in non-cachectic patients after
12 months. The modiﬁed Rankin Scale was 48% higher (2.1 ± 1.6, P < 0.05), Barthel Index was 22% lower (71 ± 39, P < 0.01),
and handgrip strength was 34% lower (21.9 ± 13.0, P< 0.05) in cachectic compared to non-cachectic patients after 12months.
The low physical performance if deﬁned by Barthel Index <60 points was linked to the lean tissue wasting (OR 44.8, P < 0.01),
presence of cachexia (OR 20.8, P < 0.01), and low body mass index <25 kg/m2 (OR 11.5, P < 0.05). After adjustment for co-
founders, lean tissue wasting remained independently associated with the low physical performance at 12 months follow-up
(OR 137.9, P < 0.05).
Conclusions In this cohort study, every ﬁfth patient with ischemic stroke fulﬁlled the criteria of cachexia within 12 months
after index event. The incidence of cachexia was 21%. Cachectic patients showed the lowest functional and physical capacity.
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Introduction
Stroke is a leading medical, socio-economic and health care
problem worldwide. Increasing global life expectancy and a
reduction of the acute post-stroke mortality rate contribute
to the rising costs in stroke care.1–3 About two thirds of the
patients remain disabled after stroke.4,5 The course of post-
stroke recovery depends on the initial stroke severity and
stroke-related complications including inﬂammation, infec-
tion, metabolic dysfunction, and degree of disability. Sev-
eral clinical trials have shown an important role of body
weight and nutritional status at stroke onset for the
functional outcome and mortality after stroke6–8 and an
association between the body weight and mortality in
experimental stroke.9
Body weight loss after stroke is a common observation in
acute and chronic stroke.6 However, detailed information
on body composition changes after stroke are scarce.10,11
Standardized assessment of body composition is feasible
using dual-energy X-ray absorptiometry (DXA), bioelectrical
impedance, or computer tomography.12–14 Tissue wasting or
cachexia is a complex metabolic syndrome of multifactorial
origin15 that has been most frequently shown in association
with several chronical diseases including chronic heart failure,
chronic obstructive pulmonary disease, kidney disease, or
cancer.16–19 The reported prevalence of cachexia ranges be-
tween 5% and 80% depending on disease and disease sever-
ity and has been linked to poor outcome.20,21 However, the
incidence of cachexia has not been studied in detail in pa-
tients with ischemic stroke.
The aim of this prospective observational study was to an-
alyse changes of body weight and body composition and to
investigate the functional outcome in cachectic and non-
cachectic patients with stroke.
Methods
Ethical conduct and study population
The investigator-initiated single-centre longitudinal prospec-
tive observational body size in stroke study22 (German regis-
try for clinical trials number DRKS00000514) was approved
by the Ethic Committee of Charité-Universitätsmedizin Berlin,
Germany (EA2/008/09), and written informed consent was
obtained from all patients.
We studied 67 patients with acute ischemic stroke within
the territory of the middle cerebral artery. The patients
with mild to moderate neurological deﬁcit [deﬁned by the
National Institute of Health Stroke Scale (NIHSS) ≤12
points] were consecutively enrolled within 48 h after stroke
onset while being admitted to a stroke unit (Department of
Neurology, Charité-Universitätsmedizin Berlin, Campus
Virchow-Klinikum, Berlin, Germany) from June 2009 to No-
vember 2012. Following the discharge from the stroke unit,
34 patients were admitted to post-stroke rehabilitation.
These patients underwent adjusted early post-stroke reha-
bilitation programs in specialized rehabilitative clinics ac-
cording to national standards for rehabilitation procedures
after stroke.
Study related examinations included assessments of body
composition, physical and functional capacity, muscle
strength, and nutritional status and were completed in hospi-
tal at baseline (4 ± 2 days after the index event) and at
12 months follow-up (389 ± 26 days after stroke onset) visit.
According to the changes of the body weight after 12months,
patients were retrospectively grouped into (i) weight
gain/stable weight, (ii) moderate weight loss (<5% of body
weight), and (iii) cachectic subgroups. Cachexia was deﬁned
by weight loss ≥5% of the original weight over a period of
12 months and at least three clinical criteria according to
the current consensus deﬁnition.15
Assessment of functional outcome and muscle
strength after stroke
Functional capacity and degree of disability were assessed by
the Barthel Index (BI) and by the modiﬁed Rankin Scale
(mRS).23 The BI contains 10 basic activities of the daily living
related to self-care and mobility with scores of ‘0’ to ‘100’,
where the lower scores indicate greater dependency. Low
functional status was deﬁned by the BI <60 points.
The mRS measures physical independency by assessment
of the body function, activity, and participation in daily tasks
on the scale ranging from ‘0’ (no symptoms) to ‘6’ (death).
Isometric muscle strength of the hand was assessed by the
handgrip strength test using a handgrip dynamometer
(Saehan Corporation, Korea). The highest of three handgrip
measurements of the non-paretic hand was used for
analyses.
Maximal isometric muscle strength of the quadriceps mus-
cle (expressed in Newton, N) was measured as described pre-
viously.24 Brieﬂy, the freely hanging legs of the sitting
patients were connected at the ankle with a pressure trans-
ducer (Multitrace 2, Lectromed, Jersey, Channel Islands),
and maximal isometric strength was assessed from the best
of three contractions on each leg, with a resting period of
at least 60 s in between.
Body composition
Body mass index (BMI) was calculated as a ratio of body
weight and squared height (kg/m2). For detailed body compo-
sition assessment, dual-energy DXA was performed using
LunarProdigy densitometer (GE Healthcare, Chalfont St. Giles,
UK). Total body scans were analysed to obtain total and
regional (upper and lower limbs, and trunk) measurements
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of the fat and lean tissue. The sum of the lean or fat mass of
the upper and lower limbs was termed as an appendicular
muscle mass (ALM) or appendicular fat mass. The fat-free
mass index (FFMI) was calculated as a ratio of ALM and
squared height (kg/m2). Lean tissue wasting was deﬁned by
low FFMI (for female patient ≤5.45 kg/m2 and for male pa-
tient ≤7.25 kg/m).
Appetite was assessed according to the visual analogue
scale ranging from ‘0’ (no appetite) to ‘10’ (very good
appetite).25 In addition, nutritional status was assessed by
Mini Nutritional Assessment at 12 months as follows:
patients were undernourished, if they achieved 16 points
or less, at risk for malnutrition if they achieved 17–23.5
points, or had a normal nutritional status if they achieved
≥24 points.26
None of the patients included in our study had dysphagia
on a clinical relevant level (preventing oral feeding), and none
was fed enterally or parenterally.
Blood sampling
Venous blood samples were obtained in all patients
after 12 h of overnight fasting. Standard biochemical pa-
rameters were assessed by routine laboratory measure-
ment. Systemic inﬂammation was present if C-reactive
protein (CRP) plasma level was over 6.1 mg/dL, as deﬁned
previously.27
Statistical analysis
All data were presented as means ± standard deviation,
median (interquartile range), or percentage as appropriate.
All variables were tested for normal distribution using the
Kolmogorov–Smirnov test. Non-normally distributed data
were log transformed to achieve a normal distribution
where indicated. Statistical comparisons were made using
paired or unpaired Student’s t-tests as appropriate, analysis
of variance followed by Fisher’s post hoc test, Mann–
Whitney, or Kruskal–Wallis test. Chi-squared test was used
to assess categorical distribution between the groups.
Pearson’s simple regression and logistic regression were
used as appropriate. A value of P < 0.05 was considered
statistically signiﬁcant. Statistical analyses were performed
with the StatView 5.0 software package (SAS Institute Inc,
Cary, NC) and the software GraphPad Prism 6.0.
Results
Baseline clinical characteristics of the patients and
retrospective study subgroups are presented in Table 1.
Twelve months after stroke, 42 (63%) patients had stable
weight or weight gain, 11 (16%) of all patients were found
with moderate weight loss, and 14 (21%) patients became
cachectic (Figure 1). There were no signiﬁcant differences
regarding the BMI, the side of stroke-related brain damage,
thrombolytic therapy, frequency of paresis, or admission to
post-stroke rehabilitation at baseline between all
subgroups. Patients who became cachectic 12 months after
stroke were signiﬁcantly older (P < 0.05), had more
frequently advanced neurological deﬁcit with NIHSS ≥5
(64%, P < 0.05), had higher degree of dependence by
mRS (P < 0.01) and BI (P < 0.05), and had the lowest
albumin and the highest CRP serum levels (P < 0.001 and
P < 0.01, respectively) at baseline compared to other
subgroups (Table 1).
According to univariate regression analysis, baseline pa-
rameters including age, neurological deﬁcit as indicated by a
NIHSS ≥5 points, functional dependency as indicated by
mRS and BI, albumin and log-transformed CRP serum levels,
systemic inﬂammation as deﬁned by CRP serum levels
>6.1 mg/dL, self-reported appetite, and handgrip strength
were associated with cachexia onset (Table 2). After adjust-
ment for age, sex and BMI, systemic inﬂammation, and CRP
serum levels were independently associated with cachexia
development (Table 2).
Body composition
At baseline, no differences in body composition were ob-
served among study subgroups (Table 3). While in the stable
weight/weight gain group no loss of leanmass after 12months
was observed, patients with weight loss showed a reduction in
lean mass (Table 3). Thus, in patients who became cachectic, a
signiﬁcant reduction of ALM by 6.5% (P < 0.05) was observed
(Table 3). The frequency of the lean tissue wasting as
deﬁned by FFMI ≤5.45 kg/m2 for female patient and FFMI
≤7.25 kg/m2 for male patient in the cachectic subgroup was
43% after 12 months (P < 0.001) vs. baseline. In addition,
appendicular fat mass 12 months after stroke was also the
lowest in cachectic patients (P < 0.05).
In the stable weight/weight gain group and the moderate
weight loss group, no signiﬁcant reduction of lean tissue
according to the FFMI was observed (Table 3). Lean tissue
wasting showed no relation to paresis in the studied patients,
(OR 1.1, 95% CI [0.12–10.6], P = 0.9).
Functional outcome at 12 months follow-up
Clinical characteristics of the patient subgroups at
12 months follow-up are shown in Table S1. Twelve months
after stroke an improvement of functional capacity com-
pared to baseline was found in most patients with stroke
(Figure 2A and 2B). This improvement applied to patients
with and without cachexia. Nonetheless, cachectic patients
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remained with the more severe disability as shown by the
higher mRS score (2.1 ± 1.6, P < 0.01) and lower BI score
(71 ± 39, P < 0.01) compared to other study subgroups
(Figure 2A and 2B). Better functional capacity according to
the BI was associated with weight gain (R = 0.25,
P < 0.05) in all patients with stroke (Figure 2C).
Cachectic patients showed the lowest muscle strength as
assessed by handgrip strength test and quadriceps strength
test (Figure 3A and 3B). An association between the FFMI
and handgrip strength was observed in non-cachectic
(R = 0.54, P < 0.0001) and in cachectic (R = 0.71, P < 0.01)
patients at 12 months follow-up (Figure 3C).
Univariate logistic regression analysis showed an associa-
tion of low functional status as deﬁned by BI score <60
points with the lean tissue wasting, presence of cachexia,
BMI, body weight loss, nutritional status, low albumin,
and high CRP serum levels (Table 4). After adjustment for
covariates included age and sex, lean tissue wasting and
FFMI remained independently associated with low func-
tional status.
Nutritional status at 12 months follow-up
Signiﬁcant improvement of the appetite according to the
visual appetite scale was observed in patients with weight
gain/stable weight but not in those with any degree of
weight loss (Figure 4A). Cachectic patients were found with
the lowest appetite and nutritional status (Figure 4A and
4B). A direct association between the weight gain and ap-
petite was observed (R = 0.4, P < 0.002, Figure 4C).
Systemic inﬂammation
At 12 months follow-up, inﬂammatory activity was still
ongoing in cachectic patients [median CRP 7.6 (interquartile
range 2.6–15.2) mg/dL, P < 0.01] compared to the other sub-
groups (Table S1). Lean tissue wasting, nutritional status, self-
reported appetite, mRS, BI, and handgrip strength were asso-
ciated with systemic inﬂammation (Table 5).
Table 1. Clinical characteristics of study cohort at baseline
Parameter
Study group Weight gain/stable weight Moderate weight loss Cachexia
P-valuen = 67 n = 42 n = 11 n = 14
Age, years 69 ± 11 66 ± 11 70 ± 10 75 ± 9 0.03
Male sex; % (n) 58 (39) 60 (25) 82 (9) 36 (5) 0.07
Body mass index, kg/m2 27.0 ± 4.1 26.5 ± 3.7 28.7 ± 5.1 26.4 ± 4.8 0.3
Body mass index <25 kg/m2; % (n) 30 (20) 31 (13) 18 (2) 36 (5) 0.6
Systolic RR, mmHg 138 ± 24 136 ± 21 150 ± 27 138 ± 30 0.2
Diastolic RR, mmHg 77 ± 13 77 ± 12 82 ± 14 73 ± 14 0.1
Mean RR, mmHg 97 ± 15 96 ± 14 105 ± 17 94 ± 14 0.2
Stroke severity
Thrombolysis with rt-PA; % (n) 31 (21) 29 (12) 27 (3) 43 (6) 0.6
Right hemispheric stroke; % (n) 66 (42) 60 (25) 73 (8) 75 (9) 0.7
Paresis; % (n) 84 (56) 86 (36) 82 (9) 79 (11) 0.8
Post-stroke rehabilitation; % (n) 51 (34) 52 (22) 46 (5) 50 (7) 0.9
NIHSS score 4.5 ± 3.2 4.3 ± 3.2 3.5 ± 2.7 5.8 ± 3.0 0.2
NIHSS score 5–12; % (n) 37 (25) 33 (14) 18 (2) 64 (9) 0.02
Modiﬁed Rankin Scale score 2.0 ± 1.3 1.8 ± 1.1 1.6 ± 1.0 3.0 ± 1.4 0.003
Modiﬁed Rankin Scale score 4–5; % (n) 18 (12) 12 (5) 9 (1) 43 (6) 0.02
Barthel Index score 78 ± 29 82 ± 26 88 ± 20 60 ± 38 0.03
Barthel Index score < 60 27 (18) 21 (9) 12 (2) 50 (7) 0.09
Comorbidities
Diabetes mellitus; % (n) 27 (18) 17 (7) 55 (6) 36 (5) 0.03
Hypertension; % (n) 84 (56) 83 (35) 82 (9) 86 (12) 0.9
Dyslipidemia; % (n) 59 (39) 55 (23) 82 (9) 50 (7) 0.2
Biochemistry
Haemoglobin, g/dL 14 ± 2.0 14.0 ± 1.9 14.5 ± 1.1 13.6 ± 2.7 0.5
Albumin, g/L 36.8 ± 5.6 37.4 ± 5.9 39.1 ± 3.3 32.2 ± 5.9 0.001
Glucose, mg/dL 115 ± 44 114 ± 46 136 ± 45 100 ± 24 0.2
HbA1c, % 6.2 ± 1.4 6.0 ± 1.2 6.7 ± 1.5 6.4 ± 1.8 0.2
Sodium, mmol/L 140 ± 4 141 ± 3 139 ± 6 141 ± 4 0.6
Potassium, mmol/L 4.1 ± 0.4 4.1 ± 0.3 4.0 ± 0.5 4.0 ± 0.5 0.9
Triglyceride, mg/dL 151 ± 71 154 ± 75 142 ± 43 156 ± 81 0.7
Cholesterol, mg/dL 196 ± 44 198 ± 45 176 ± 49 203 ± 38 0.5
Low density lipoprotein, mg/dL 114 ± 42 113 ± 45 114 ± 37 128 ± 26 0.3
High density lipoprotein, mg/dL 51 ± 15 54 ± 17 50 ± 11 46 ± 14 0.2
Creatinine, mg/dL 1.0 ± 0.5 1.1 ± 0.5 1.1 ± 0.3 0.9 ± 0.2 0.8
C-reactive protein, mg/L 3.8 [1.8–6.3] 3.4 [1.7–6.6] 1.7 [1.0–4.8] 8.8 [4.6–22.4] 0.002
Uric acid, mg/dL 5.7 ± 1.4 5.6 ± 1.5 5.7 ± 1.3 5.9 ± 1.2 0.9
NIHSS, National Institute of Health Stroke Scale.
4 N. Scherbakov et al.
Journal of Cachexia, Sarcopenia and Muscle 2019
DOI: 10.1002/jcsm.12400
Discussion
Our study demonstrates an incidence of cachexia of 21%
within 1 year after stroke. Physical and functional clinical sta-
tus at 12 months follow-up was lower in cachectic patents
compared to non-cachectic patients with stroke. We also
identiﬁed clinical parameters predictive for development of
cachexia after stroke.
Tissue wasting
Using DXA analyses, we showed that patients with cachexia,
in contrast to patients without cachexia, lost fat mass and
lean tissue. Loss of lean mass in paretic patients with stroke,
having sedentary lifestyle, is a common observation.28–30
However, we observed a lean tissue depletion in cachectic
patients regardless of the paresis. Previously, a stroke-related
systemic lean tissue wasting due to catabolic activation was
reported in a mouse model of middle cerebral artery occlu-
sion.9 The extent of the brain damage in mice correlated with
apoptotic and proteolytic activity in skeletal muscle in both
legs.9 In line with this experimental data, we observed an
association between the stroke severity and the presence of
cachexia.
Certainly, lean tissue decline is an age-dependent phe-
nomenon, with the prevalence ranging between 8% and
60% in healthy elders.31–35 Previous study showed a preva-
lence of sarcopenia of 7% in chronic stroke survivors within
3 years after ischemic or haemorrhagic stroke.10 In the pres-
ent cohort, the prevalence of the lean tissue depletion at
the time of the index stroke was within the generally
observed age-dependent range. However, an increase from
6% to 13% in the prevalence of lean tissue depletion within
12 months with the highest proportion among cachectic
patients (43%) might be linked to stroke-related metabolic
imbalance.36
Systemic inﬂammation
An association between cachexia and inﬂammatory state in
patients with chronic heart failure or chronic obstructive
Figure 1 Body weight changes at 12 months follow-up in the study pop-
ulation. Incidence of cachexia.
Table 2. Baseline parameters associated with cachexia onset after stroke
Parameter OR 95% CI P-value
Presence of
systemic inﬂammation
8.54 [2.27–32.17] 0.002
C-reactive protein, log[mg/L] 7.93 [1.99–31.60] 0.003
NIHSS 5–12 points 4.16 [1.20–14.39] 0.02
Barthel Index <60 points 3.80 [1.10–13.20] 0.03
Modiﬁed Rankin Scale, point 2.19 [1.32–3.65] 0.003
Age, year 1.08 [1.01–1.15] 0.02
Barthel Index, 10 points 0.78 [0.64–0.95] 0.02
Handgrip strength, kg 0.91 [0.85–0.98] <0.01
Albumin, g/dL 0.79 [0.68–0.92] 0.002
Appetite, point VAS 0.51 [0.34–0.77] 0.002
Appendicular lean mass, kg 0.83 [0.70–0.99] 0.03
Lean mass upper limbs, kg 0.58 [0.34–0.99] <0.05
Lean mass lower limbs, kg 0.76 [0.60–0.96] 0.02
Multivariable logistic model
adjusted for age, sex, and BMI
I. Systemic inﬂammation 9.66 [1.96–47.63] 0.005
II. C-reactive protein, log[mg/L] 6.67 [1.34–33.12] 0.02
NIHSS, National Institute of Health Stroke Scale; VAS, visual analogue scale.
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pulmonary disease has been shown previously.25,37 In the
present study, cachectic patients showed similar signs of in-
ﬂammatory activation with elevated CRP levels assessed at
12 months follow-up accompanied by lean tissue depletion,
low functional capacity, and reduction of body weight. A rela-
tion between systemic inﬂammation and loss of muscle
strength and muscle thickness in population-based clinical tri-
als has been reported previously.27,38 In experimental setting,
administration of the inﬂammatory markers in rats caused
muscle protein breakdown.39 Thus, our results were in accor-
dance with previous observations.
Our recent studies investigating cachexia in patients with
chronic heart failure suggested an association of cardiac ca-
chexia with gastrointestinal congestion, increased concen-
tration of gut bacteria, and systemic inﬂammation.37,40
Further, changes in gut microbiota after stroke were linked
to increased pro-inﬂammatory cytokines levels.41 Several
pathways linking systemic inﬂammation to the brain and
Table 3. Body composition in patient subgroups
Parameter
Weight gain/stable weight Moderate weight loss Cachexia
Baseline 12 months Baseline 12 months Baseline 12 months
Body mass index, kg/m2 26.7 ± 3.5 28.2 ± 4.9*** 28.7 ± 5.1 27.9 ± 4.9** 26.4 ± 4.8 24.2 ± 4.5**#†††
FFMI, kg/m2, female patient 6.4 ± 0.8 6.6 ± 0.7 6.5 ± 0.04 6.6 ± 0.1 6.1 ± 0.8 6.0 ± 1.3†
FFMI, kg/m2, male patient 8.3 ± 0.7 8.3 ± 0.8 8.1 ± 0.7 7.9 ± 0.7 7.6 ± 0.5 7.4 ± 0.6*#
Lean mass, kg
Appendicular 22.2 ± 4.9 22.4 ± 4.7 22.7 ± 3.9 22.3 ± 3.5 18.6 ± 4.5 18.0 ± 4.6*#††
Lower limbs 16.9 ± 3.4 17.2 ± 3.3* 17.7 ± 3.5 17.7 ± 3.0 14.2 ± 3.2 13.9 ± 3.4††
Upper limbs 5.4 ± 1.6 5.3 ± 1.5 5.8 ± 1.1 5.1 ± 1.4** 4.4 ± 1.3 4.1 ± 1.3**#†
Fat mass, kg
Appendicular 11.9 ± 3.8 12.1 ± 3.9** 10.2 ± 3.2 9.2 ± 3.2*# 10.0 ± 4.1 9.1 ± 4.4**#
Lower limbs 9.1 ± 2.9 9.8 ± 3.4 8.7 ± 2.7 7.6 ± 2.8*† 7.8 ± 2.9 7.6 ± 3.6**
Upper limbs 2.4 ± 0.8 2.5 ± 0.8 2.4 ± 0.8 1.9 ± 0.5* 2.3 ± 1.0 2.0 ± 1.3**†
FFMI, fat-free mass index.
*P < 0.05.
**P < 0.01.
***P < 0.001 vs. baseline.
#P < 0.05.
†P < 0.01 vs. weight gain/stable weight group.
††P < 0.05.
†††P < 0.001 vs. moderate weight loss group.
Figure 2 (A) Assessment of functional capacity according to the Barthel Index in study subgroups. (B) Assessment of degree of disability according to
the modiﬁed Rankin Scale in study subgroups. (C) Relationship between the functional outcome and weight change at 12 months follow-up
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responsible for development of ‘sickness behaviour’ with
attenuated parasympathetic tone, reduced appetite, altered
thermoregulation, and impaired energy metabolism were
previously described.42 Accordingly, we observed an associ-
ation between systemic inﬂammation and reduced nutri-
tional status in patients with stroke. Cachectic patients
had the lowest appetite leading to decreased food intake.
An involvement of anorexia in regulation of body composi-
tion in chronic inﬂammatory disease and cachexia develop-
ment was suggested.25 Therefore, ongoing systemic
inﬂammation in chronic stroke might lead to increased
metabolic drive, appetite loss, and energetic deﬁcit
resulting in proteolytic breakdown and tissue wasting.25,43
Functional limitations
In the present study, we showed implications of cachexia on
functional outcome after stroke. Cachectic patients had the
Figure 3 (A) Maximal handgrip strength in study subgroups. (B) Maximal quadriceps strength in study subgroups. (C) Association of fat-free mass index
with maximal handgrip strength in patients with and without cachexia at 12 months follow-up
Table 4. Risk factors associated with functional dependency deﬁned by Barthel Index <60 at 12 months follow-up
Parameter OR 95% CI P-value
Lean tissue wasting 44.8 [4.17–481.56] 0.002
Presence of cachexia 20.8 [2.09–206.15] <0.01
Undernourished/at risk for malnutrition 14.7 [0.99–215.37] 0.05
Body mass index <25 kg/m2 11.5 [1.19–110.67] 0.04
C-reactive protein, log[mg/L] 10.1 [1.39–73.54] 0.02
NIHSS, point 1.43 [1.07–1.90] 0.02
Delta weight loss, kg 0.82 [0.68–0.99] 0.04
Body mass index, kg/m2 0.68 [0.50–0.93] 0.02
MNA scale, point 0.57 [0.37–0.87] 0.01
Albumin, g/L 0.75 [0.60–0.94] 0.01
FFMI, kg/m2 0.16 [0.04–0.63] 0.01
Lean mass arms, kg 0.24 [0.06–0.92] 0.04
Lean mass legs, kg 0.58 [0.38–0.89] 0.01
Appendicular lean mass, kg 0.66 [0.47–0.93] 0.02
Handgrip strength, kg 0.89 [0.81–0.99] 0.04
Multivariable logistic model adjusted for age and sex
I. Lean tissue wasting 137.9 [2.04–9324.7] 0.02
II. FFMI, kg/m2 0.11 [0.13–0.99] <0.05
FFMI, fat-free mass index; NIHSS, National Institute of Health Stroke Scale; MNA, Mini Nutritional Assessment.
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most severe stroke-related disability across the study groups
as assessed by the BI and mRS, although they signiﬁcantly im-
proved their functional status at 12 months follow-up. We
showed that the presence of cachexia and the lean tissue de-
pletion were associated with the low functional capacity as
deﬁned by the BI.23 Further, both lower BMI and higher body
weight loss were more frequently observed in patients with
higher degree of functional dependence. Therefore, our ﬁnd-
ings are in accordance with the previous clinical trials, inves-
tigating cachexia in chronic diseases and suggesting its
unfavourable impact on activities of daily living, clinical and
functional outcome.25,37
Additionally, to the BI and mRS, the study protocol consid-
ered a performance of the short physical performance bat-
tery (SPPB).22 SPPB is widely used in geriatric medicine and
includes examination of standing ability, time walking of 3
or 4 m, and time to rise from the chair.44 It became apparent
in the study that the SPPB was less suitable to evaluate the
functional capacity due to coordination deﬁcit if patient had
a paretic limb. Hence, merely 51% of all patients (i.e. 21%
of the cachectic group) at baseline and 82% of the patients
(57% of the cachectic group) at 12 months follow-up were
able to complete the SPPB, which indicates a relevant ﬂoor
effect as discussed previously.12 We performed a 4 m of gait
test as a part of the SPPB during the baseline and 12 months
follow-up. The gait speed at baseline was 1.1 ± 0.3 vs.
0.9 ± 0.2 vs. 0.8 ± 0.4 m/s, P = 0.3 in the stable weight vs.
moderate weight loss vs. cachectic subgroup, respectively.
Twelve months after stroke, gait speed remained identical
in all three groups due to the high frequency of paresis in
these patients. Thus, due to the relevant ﬂoor effect of the
test battery in the setting of stroke as well as limited insight
into the functional capacity of the patients, we decided to
omit these data.
Figure 4 (A) Self-reported appetite score according to visual analogue scale in study subgroups. (B) Nutritional status according to Mini Nutritional
Assessment score in patient subgroups at 12months follow-up. (C) Association of body weight change with score by visual analogue scale at 12months
follow-up
Table 5. Risk factors associated with the presence of systemic inﬂammation at 12 months follow-up serving as dependent variable
Parameter OR 95% CI P-value
Lean tissue wasting 5.20 [0.99–27.09] 0.05
Changes of body weight, kg 0.89 [0.80–1.01] 0.06
Appetite according to VAS, point 0.71 [0.52–0.97] 0.03
Undernourished/at risk for malnutrition 0.81 [0.69–0.99] 0.04
Modiﬁed Rankin Scale, point 1.96 [1.16–3.31] 0.01
Barthel Index, 10 points 0.68 [0.49–0.95] 0.02
Handgrip strength, kg 0.94 [0.89–0.99] 0.02
VAS, visual analogue scale.
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Weight gain
The majority of patients in the present study increased the
weight and improved their functional capacity during the ﬁrst
year after stroke. We observed a correlation between in-
creasing weight and better functional outcome with higher
BI, indicating a positive effect of ‘obesity paradox’.6
Limitations
Our study has several limitations. First, the number of pa-
tients with stroke is limited. Second, only study patients with
mild to moderate stroke deﬁcit were included, thus our re-
sults are not generalizable to patients with severe stroke.
Therefore, further longitudinal studies are warranted to con-
ﬁrm and extend our ﬁndings.
Conclusions
The observed incidence of cachexia was 21% among the pa-
tients with stroke at 12months follow-up. Overall, more frag-
ile patients deﬁned by higher age, advanced neurological
deﬁcit, and functional disability were at risk for cachexia. At
12 months follow-up, cachectic patients remained with the
lowest functional and physical status. Development of cachexia
after stroke should be recognized as a relevant complication.
Better understanding of the interaction between stroke-related
brain injury and systemic metabolism seems to be required for
better prevention of cachexia in patients with stroke.
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